GAIN THERAPEUTICS INC. - COMMON STOCK

Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease

27 Jun 2024 08:35:48 By Nasdaq GlobeNewswire

Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

25 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics Announces Pricing of $11.0 Million Public Offering

13 Jun 2024 21:00:59 By Nasdaq GlobeNewswire

Gain Therapeutics Announces Proposed Public Offering

13 Jun 2024 16:44:54 By Nasdaq GlobeNewswire

Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024

30 May 2024 07:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update

14 May 2024 07:30:00 By Nasdaq GlobeNewswire

Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease

24 Apr 2024 09:25:00 By Nasdaq GlobeNewswire

Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer

08 Apr 2024 09:25:00 By Nasdaq GlobeNewswire

Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer

01 Apr 2024 09:25:00 By Nasdaq GlobeNewswire

Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update

26 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics to Present at Public Ventures Discovery Day

15 Mar 2024 14:30:34 By Nasdaq GlobeNewswire

Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease

05 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease

27 Feb 2024 14:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight

14 Feb 2024 12:29:34 By Nasdaq GlobeNewswire

UPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease

06 Feb 2024 09:56:04 By Nasdaq GlobeNewswire

Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease

06 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update

31 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024

02 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research

04 Dec 2023 08:00:00 By Nasdaq GlobeNewswire

Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model

01 Dec 2023 08:00:00 By Nasdaq GlobeNewswire